Opicapone: A Review in Parkinson’s Disease

  title={Opicapone: A Review in Parkinson’s Disease},
  author={L. Scott},
  • L. Scott
  • Published 2016
  • Medicine
  • Drugs
  • Oral opicapone (Ongentys®), a potent, third-generation, long-acting, peripheral catechol-O-methyltransferase (COMT) inhibitor, is approved as adjunctive treatment to levodopa (L-Dopa)/dopa-decarboxylase inhibitor (DDCI) therapy in adults with Parkinson’s disease (PD) and end-of-dose motor fluctuations who cannot be stabilized on those combinations. In 14- to 15-week, double-blind, multinational trials and in 1-year, open-label extension studies in this patient population, opicapone was an… CONTINUE READING
    19 Citations
    Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
    • 15
    • PDF
    Opicapone for the treatment of Parkinson’s disease: an update
    • 4


    Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
    • 37
    • Highly Influential
    Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study
    • 11
    Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
    • 51
    • Highly Influential
    Effect of moderate liver impairment on the pharmacokinetics of opicapone
    • 17
    • Highly Influential
    Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
    • 47
    Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
    • 19
    • Highly Influential
    Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects
    • 12
    • Highly Influential